NTB003

DRUG2 trials

Sponsors

Nanjing Chia-tai Tianqing Pharmaceutical

Conditions

TEDThyroid Eye Disease

Phase 1

Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics of NTB003 in Healthy Participants

Enrolling by invitationNCT07182552

Nanjing Chia-tai Tianqing PharmaceuticalTED

Start: 2025-06-30End: 2026-03-30Target: 40Updated: 2025-09-19

An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)

Not yet recruitingNCT07462130

Nanjing Chia-tai Tianqing PharmaceuticalThyroid Eye Disease

Start: 2026-03-01End: 2028-03-30Target: 74Updated: 2026-03-10